Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder
NCT06860958Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of roflumilast in major depressive disorder (MDD) (2 arms), sponsored by Tanta University. Primary endpoint: Hamilton Depression Rating Scale at 2 months. Started Mar 2025; status: recruiting.
02
Drugs
roflumilast
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06860958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860958.